Colorcon Inc., a Pennsylvania-based developer and provider of movie coating techniques and excipients, has launched its Acryl-Eze II line of enteric coatings. With the discharge, the corporate now provides a broader pH range throughout its enteric coatings for pharmaceutical purposes.
According to the corporate, delayed-release oral solid-dosage varieties developed with enteric coatings comparable to these present both safety of the gastric mucosa from irritating actives, or safety of medicine unstable in gastric fluids. Applications the coatings are fitted to embrace tablets and multi-particulate dosages for a range of drug merchandise, together with proton pump inhibitors (generally used to deal with acid reflux disease and ulcers of the abdomen and the duodenum).
Deborah Taylor, director of international market communications at Colorcon, instructed Outsourcing-Pharma that one of the chief advantages of utilizing the Acryl-Eze II coatings is that every coating is totally formulated.
“All components are included as a one-step system that brings benefits to users by reducing the inventory of raw materials, less QC testing, color consistency for pigmented coatings, and batch to batch reliability,” she defined.
The Acryl-Eze II aqueous enteric techniques reportedly can present particular purposes for tablets and multi-particulate dosage varieties with enhanced enteric safety as much as a difficult stage of pH 5.zero seen with sufferers taking PPIs, or when examined underneath fed situations.
Kelly Boyer, Colorcon’s common supervisor of movie coatings, added, “Acryl-EZE formulations provide significant time savings in both development and production; while enabling targeted drug delivery across a wide pH range.”
According to Colorcon vice chairman and chief scientific officer Ali Rajabi-Siahboomi, enteric coatings are typically difficult, because of requiring a number of components and course of steps.
“Through Colorcon’s coating technology, this new Acryl-Eze II formulation provides simplified preparation and use, with enhanced protection up to pH 5.0 through the addition of a special top-coat,” he mentioned. “Coating performance has been validated through a human volunteer study in the most challenging fed state conditions, confirming bioavailability and in-vivo performance.”